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Dopamine Receptor Antagonists 
Enhance Proliferation and 
Neurogenesis of Midbrain  
Lmx1a-expressing Progenitors
Eva Hedlund1,2,*, Laure Belnoue3,*, Spyridon Theofilopoulos4, Carmen Salto4, Chris Bye5, 
Clare Parish5, Qiaolin Deng1,3, Banafsheh Kadkhodaei1, Johan Ericson3, Ernest Arenas4,†, 
Thomas Perlmann1,3,† & András Simon3,†
Degeneration of dopamine neurons in the midbrain causes symptoms of the movement disorder, 
Parkinson disease. Dopamine neurons are generated from proliferating progenitor cells localized in the 
embryonic ventral midbrain. However, it remains unclear for how long cells with dopamine progenitor 
character are retained and if there is any potential for reactivation of such cells after cessation of normal 
dopamine neurogenesis. We show here that cells expressing Lmx1a and other progenitor markers 
remain in the midbrain aqueductal zone beyond the major dopamine neurogenic period. These cells 
express dopamine receptors, are located in regions heavily innervated by midbrain dopamine fibres 
and their proliferation can be stimulated by antagonizing dopamine receptors, ultimately leading to 
increased neurogenesis in vivo. Furthermore, treatment with dopamine receptor antagonists enhances 
neurogenesis in vitro, both from embryonic midbrain progenitors as well as from embryonic stem cells. 
Altogether our results indicate a potential for reactivation of resident midbrain cells with dopamine 
progenitor potential beyond the normal period of dopamine neurogenesis.
Midbrain dopamine neurons play key roles in neurotransmission controlling locomotion, cognition and reward. 
Major motor symptoms in Parkinson’s disease are caused by degeneration of dopamine neurons and an impor-
tant research aim has therefore been to develop methodology for engineering dopamine neurons from stem 
cells in vitro for cell replacement therapy in Parkinson’s patients1–3, reviewed in ref. 4. Detailed understanding 
of the normal process of dopamine neurogenesis has been essential in these efforts, reviewed in ref. 5. During 
development, spatially organized signalling events lead to the expression of transcription factors, including the 
LIM-homeodomain protein Lmx1a in early proliferating neural progenitors localized close to the ventricular wall 
of the midbrain aqueduct6,7. Lmx1a, together with the related transcription factor Lmx1b, specify neural progen-
itors and is essential for the initiation of a molecular program for dopamine neurogenesis8,9. As Lmx1a-specified 
progenitor cells exit the cell cycle additional transcription factors are induced, including Nurr1 and Pitx35. 
These factors promote dopamine neuron differentiation and the acquisition of dopaminergic characteristics as 
cells migrate first radially and then tangentially towards the prospective ventral tegmental area and substantia 
nigra10,11.
The bulk of dopamine neurogenesis occurs normally between embryonic days (E) 10–14 in mice12. An excit-
ing possibility would be if substantial dopamine neurogenesis could be induced after the main period of embry-
onic dopamine neurogenesis. The potential for late dopamine neurogenesis has previously been investigated. 
Some studies indicate that loss of dopamine neurons in the adult brain evokes responses that could lead to de novo 
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Figure 1. Ventral midbrain Lmx1a-expressing ventricular cells maintained progenitor properties. Lmx1a 
is expressed in ventral midline cells that generate midbrain dopamine neurons at E12.5, shown by staining 
against Lmx1a protein and using Lmx1aGFP/+ reporter mice (A). The expression of Lmx1a was maintained in 
ventricular progenitors at E15.5 (B,C) and E18.5 (D) shown by immunofluorescence and in situ hybridization. 
Lmx1aGFP/+ reporter mice revealed a persistent presence of eGFP+ ventricular cells during development and 
in the adult animals, depicted at E12.5 (E), E15.5 (F), 3 months (G) and 8 months of age (H). However, the 
eGFP+ cells decreased in numbers with time and changed in morphology with a gradual shortening of the 
processes (E–H). Ventral eGFP+ ventricular cells expressed nestin both in the embryo and the adult animal 
(I–K). At E15.5 the majority of cells lining the aqueduct were nestin+ (I), while at E18.5, nestin was restricted 
mainly to the eGFP+ cells (J). eGFP+ cells were distinguished from other ventricular cells by their lack of Sox1 
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generation of dopamine neurons, while others find no evidence for such events13–16. However, both the identity of 
potential progenitor cells as well as the mechanisms regulating their fate have remained elusive.
Here we addressed the duration of Lmx1a expression in midbrain ventricular cells, and whether 
Lmx1a-expressing cells could constitute a cell population with progenitor potential for reactivation at later stages 
of embryogenesis. We also asked if neurogenesis in the developing ventral midbrain could be regulated by the 
neurotransmitter dopamine itself since previous findings revealed that in aquatic salamanders, dopamine nega-
tively controls the production of dopamine neurons both during homeostasis and regeneration17. Salamanders 
are the only vertebrates known to date with the ability to fully restore the dopaminergic system by a process that is 
driven by reactivation of dopamine neurogenesis18,19. Together our analyses indicate a potential for neurogenesis 
from persisting Lmx1a-expressing cells.
Results
Ventral midbrain ventricular cells maintained expression of Lmx1a and other progenitor markers. 
To investigate if Lmx1a expression was temporally restricted to the period of dopamine neurogenesis (E10-E14)12 
we first performed immunostaining and in situ hybridizations at various time points during development. We 
found that Lmx1a expression was maintained in ventricular cells of the ventral midbrain at E15.5. In situ hybrid-
ization also demonstrated persistent Lmx1a mRNA expression at E15.5 and E18.5 (Fig. 1A–D). However, while 
Lmx1a protein was expressed at E15.5, no protein expression could be detected by immunohistochemistry at 
E18.5 and at postnatal stages. We confirmed these findings by examining heterozygous Lmx1aeGFP/+ reporter 
mouse embryos8, which in accordance with immunostaining and in situ hybridization showed declining expres-
sion, but persistent presence of eGFP+ cells throughout development and also in the adult animal at three and 
eight months of age (Fig. 1E–H).
To characterize ventral eGFP+ ventricular cells we analysed the expression of stem and progenitor markers 
during late embryogenesis. We found that eGFP+ cells expressed nestin both in the embryo and the adult animal 
(Fig. 1I–K). At E15.5 most ventricular cells lining the aqueduct were nestin+ (Fig. 1I), while at E18.5, the expres-
sion of nestin was restricted mainly to eGFP+ cells in the floor plate (FP) (Fig. 1J) and the roof plate (RP) (data 
not shown). Although nestin was maintained in the adult animal, the morphology of the eGFP+ cells changed 
markedly with age, displaying gradual shortening of their processes, as visualised by eGFP (Fig. 1G,H) and nestin 
expression (Fig. 1K). In contrast to the neighboring ventricular cells, eGFP+ cells were devoid of Sox1 (Fig. 1L), 
but showed an overlapping expression with Sox2 (Fig. 1M) and Sox3 (Fig. 1N). The Sox1, Sox2 and Sox3 expres-
sion patterns were maintained at E18.5 (Supplementary Fig. 1A–F). Notably, the eGFP+ cells also expressed the 
stem cell marker prominin (Fig. 1O,P). Adult ventricular eGFP+ cells also displayed a robust expression of Sox2 
(Supplementary Fig. 2A–E), indicative of their maintained progenitor potential. In addition, a subset of the adult 
eGFP+ cells expressed Sox3 and prominin (Supplementary Fig. 2F–M). Ki67 staining showed that the number 
of proliferating eGFP+ ventricular cells steadily decreased with developmental age (Fig. 1Q–T) indicating that 
these cells exited the cell cycle concomitant with the termination of dopamine neurogenesis. Collectively, our 
data demonstrate that cells of the Lmx1a-lineage maintain progenitor markers during late embryogenesis until 
E18.5. Thus, dopamine progenitor properties may extend beyond the main period of dopamine neurogenesis.
eGFP+ cells expressed dopamine receptors and were localized within a domain innervated by 
midbrain dopamine neurons. We previously showed that mature dopamine neurons are in close contact 
with neural stem cells in the adult salamander, a highly regenerative species in which the dopaminergic system can 
be completely restored following chemical ablation of dopamine neurons, and in which dopamine negatively regu-
lates midbrain dopamine neurogenesis17. We set out to address to what extent such a regulatory mechanism might 
be evolutionary conserved. First, we found that eGFP+ cells expressed dopamine D2 receptors (D2R) both during 
embryogenesis and in the adult brain (Fig. 2A–D; orthogonal view of E18.5 shown in Supplementary Fig. 3A,B). 
Next, immunofluorescent analyses revealed that tyrosine hydroxylase (TH+) fibers projected onto the ventral 
aqueduct in the midbrain (Fig. 2E). High magnification confocal images and orthogonal sections indicated that 
TH fibers partially surrounded a proportion of the eGFP+ progenitor cells (Supplementary Fig. 3C,D). To inves-
tigate the origin of the TH+ fibers projecting to the midbrain aqueduct, we analysed DATCreYFP mice, in which 
YFP is exclusively expressed in dopamine transporter (DAT)-expressing midbrain dopamine neurons. We found 
that TH+ fibers surrounding the ventricular Lmx1a-expressing cells expressed YFP in these embryos, indicating 
their midbrain origin (Fig. 2F,G). Periaqueductal TH+ neurons, located just lateral to the ventral aqueduct, do 
not express DAT and for this reason did not express YFP in transgenic embryos. These periaqueductal TH+ neu-
rons also extended processes in close proximity to the aqueduct (Fig. 2F,G). Histological analysis of conditional 
Nurr1DATCre (Nurr1CKO) mice, in which most dopamine neurons are lost20, showed a 7.9-fold reduction in TH+ 
fiber innervation (Fig. 2H–L) suggesting that a majority of fibers originated from midbrain dopamine neurons in 
the ventral midbrain area. As periaqueductal TH+ neurons are not lost in Nurr1-ablated mice (Fig. 2H,K,L), it is 
possible that some of the remaining fibers originated from this neuronal subpopulation. Furthermore, we found 
that eGFP+ cells lining the fourth ventricle in the hindbrain were also in close proximity to TH+ fibers originating 
expression (L), but showed overlapping expression with Sox2 (M), Sox3 (N) and prominin (O,P). The number 
of proliferating eGFP+ ventricular cells steadily decreased during development, with 123.9 ± 12.5 Ki67+ cells 
at E12.5 (Q,T, n = 6 mice), 74.4 ± 9.1 Ki67+ cells at E15.5 (R,T, n = 8 mice) and 2.5 ± 1.7 Ki67+ cells at E18.5 
(S,T, n = 5 mice) (**P < 0.01, ***P < 0.001, ANOVA, Tukey’s post hoc test). Scale bars: 50 μ M in (B) (applicable 
to A,K), 50 μM in (D) (applicable to C), 50 μ M in (H) (applicable to E–G,P,Q–S), 20 μ M in (N) (applicable to 
I,J,L,M) and 150 μ M in (O).
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from the locus coeruleus (Supplementary Fig. 3E,F). Notably, analysis showed that TH+ fibers were in close prox-
imity with the outer layers of the midbrain aqueductal cells also in the human brain (Fig. 2M,N). Together these 
data indicated a possibility for dopamine regulation of Lmx1a-expressing ventricular cells.
Figure 2. Lmx1a-expressing ventricular cells expressed dopamine receptors and their domain was innervated 
by midbrain dopamine neurons. There was a gradual increase in the fraction of eGFP+ cells expressing D2 receptor 
during embryonic development (A–C). eGFP+ cells expressed D2 receptors in adult animals (D). Immunofluorescent 
analysis of 3-month-old mice showed that the ventral aqueduct in the midbrain was innervated by tyrosine 
hydroxylase (TH+) fibers (E). Analysis of DATCrexROSA26YFP (DATCreYFP) mice demonstrated that TH+ fibers 
surrounding the ventricular eGFP+ cells were YFP+ and thus of a midbrain dopamine neuron origin (F, enlarged 
in G). Periaqueductal TH+ neurons, which lack DAT, also extended processes in close proximity to the aqueduct 
(F,G). Nurr1CKO mice, which lack SNc dopamine neurons, and have reduced numbers of VTA dopamine neurons, 
showed a 7.9-fold reduction in TH+ fiber innervation at 5 months of age (P = 0.0021, n = 3 + 4, unpaired Student’s 
t test) (H–L). Human midbrain sections demonstrated that TH+ fibers were in contact with the outer layers of the 
aqueductal cells (M,N). Scale bars: 50 μM in (A) (applicable to B,C), 50 μM in (D), 200 μ M in (F), 50 μM in (G),  
200 μ M in (K) (applicable to I), 50 μ M in (L) (applicable to E,J).
www.nature.com/scientificreports/
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Figure 3. Haloperidol treatment increases the proliferation of eGFP+ cells and neurogenesis in vivo. 
Haloperidol treatment increased the percentage of pH3+ eGFP+ ventricular cells (A,B, Haloperidol during 
E12.5–13.5, n = 8 (Ctrl), n = 9 (Hal); Haloperidol during E13.5–14.5, n = 11 (Ctrl), n = 9 (Hal); Haloperidol 
during E14.5–15.5, n = 13 (Ctrl), n = 10 (Hal), 2-way-ANOVA, treatment effect P = 0,003). Haloperidol 
treatment increased the percentage of BrdU+ eGFP+ cells at E16.5 in the ventral part of the third ventricle 
(C,D, Haloperidol during E15.5–16.5, n = 10 (Ctrl), n = 11 (Hal); Haloperidol during E16.5–17.5, n = 12 (Ctrl), 
n = 12 (Hal), 2-way-ANOVA, treatment effect P = 0,016). The number of Ki67+ ventricular cells in the ventral 
midbrain was increased in D2R KO mice at E11.5 compared to wild-type littermates (E, n = 5 (Wt), n = 5 (KO), 
P = 0.04, unpaired Student’s t test). Haloperidol treatment at E15.5–E17.5 increased the number of BrdU+ 
cells in the prospective substantia nigra and ventral tegmental area (F,G, n = 6 (Ctrl), n = 7 (Hal), P = 0.0014, 
unpaired Student’s t test). Haloperidol treatment at E15.5–E17.5 did not change the percentage of BrdU+ cells 
expressing TH in the prospective substantia nigra and ventral tegmental area (H, n = 4 (Ctrl), n = 4 (Hal), 
P = 0.32, unpaired Student’s t test). Orthogonal sections showing BrdU+ TH+ (top panel, arrow) and BrdU+ 
TH− (bottom panel, arrow) (I). Haloperidol treatment at E15.5–E17.5 increased the density of BrdU+ TH+ cells 
in the prospective substantia nigra and ventral tegmental area (P = 0.002, unpaired Student’s t test). Scale bars: 
50 μ M in (B,D,E), 100 μ M in (G) and 20 μ M in (H).
www.nature.com/scientificreports/
6Scientific RepoRts | 6:26448 | DOI: 10.1038/srep26448
Haloperidol increased eGFP+ cell proliferation and neurogenesis. To examine if eGFP+ cells may 
be regulated by dopamine, we administered the broad-spectrum dopamine receptor antagonist, haloperidol, to 
pregnant Lmx1aeGFP/+ females. Animals received two daily injections of haloperidol or vehicle and were sacrificed 
the following day. We first carried out this series of experiments during E12.5–E14.5 and found that haloperidol 
administration led to an increased number of eGFP+ cells that were also positive for the mitotic marker pH3 
(Fig. 3A,B). Interestingly, haloperidol induced a particularly strong increase in the number of pH3+ eGFP+ cells 
in the caudal portions of the midbrain (Supplementary Fig. 4A). This is in concordance with the more prominent 
TH innervation in caudal midbrain (Supplementary Fig. 5). We also administered the nucleotide analogue BrdU 
to animals via osmotic pumps, but positive cells could not be counted because virtually all cells had incorporated 
the analogue due to the intense proliferation during this active neurogenic period (data not shown). In con-
trast, when haloperidol was administered after the decline of normal dopamine neurogenesis, we could evaluate 
BrdU-incorporation and found a 1.5-fold increase of BrdU+ eGFP+ cells both at E16.5 and E17.5 (Fig. 3C,D). 
Similarly to the pH3-index, we noted a marked shift towards the caudal portions of the midbrain harbouring 
more BrdU+ eGFP+ cells (Supplementary Fig. 4B). We also found that haloperidol appeared to increase the pro-
liferation of the eGFP-negative cells (Supplementary Fig. 4C). In agreement with these data we noted a marked 
increase in the number of cycling cells in the midbrain progenitor zone at E11.5 in gene targeted mice lacking 
both alleles of the D2R gene (Fig. 3E).
Next we tested whether haloperidol treatment could increase the proliferation of the eGFP+ cells and the 
production of new dopamine neurons after E14.5. We thus administered haloperidol and BrdU between E15.5 
to E17.5, as described above, but this time evaluated the number BrdU+ cells in the prospective substantia nigra 
and ventral tegmental area instead of the ventricular zone. A 1.5-fold increase in the density of BrdU+ cells was 
detected in haloperidol treated animals (Fig. 3F,G). These BrdU+ cells were equally distributed between VTA 
and SNc (Supplementary Fig. 4D). Next we analysed the identity of BrdU+ cells and found that the percentage of 
BrdU+ cells expressing TH was unaffected, indicating that dopamine neuron differentiation was similar in both 
groups (Fig. 3H). Hence, the total number of newborn TH+ neurons showed a 1.5-fold increase in haloperidol 
compared to vehicle treated animals (Fig. 3I). These data collectively show that antagonizing dopamine signalling 
increases the proliferation of ventral aqueductal cells and ultimately the number of newborn TH+ neurons in the 
midbrain.
To corroborate these findings we tested the effect of various neurotransmitters on primary cultures of embry-
onic midbrain cells from animals undergoing dopamine neurogenesis. We took advantage of the fact that these 
cultures contained a mixture of precursor, including both dopamine and γ -aminobutyric acid (GABA) progen-
itors and used an array of neurotransmitter agonists and antagonists targeting dopamine and GABA receptors. 
In accordance with the in vivo observations we found that haloperidol treatment increased the proliferation of 
primary embryonic midbrain cells 1.5 fold as assayed by BrdU-incorporation (Fig. 4A). Moreover treatment 
with the dopamine 2 receptor (D2R) antagonist, sulpiride, but not the dopamine 1 receptor (D1R) antagonist 
SCH-23390, increased proliferation (Fig. 4A). In contrast, neither dopamine itself nor the dopamine recep-
tor agonists quinpirole or dihydrexidine increased proliferation. We also found that the GABAA receptor ago-
nist muscimol decreased proliferation, while the GABAA receptor blocker, picrotoxin, increased proliferation 
(Fig. 4A, Supplementary Fig. 6). Consistently with these results we observed an increased fraction of TH+ cells in 
the cultures upon haloperidol and sulpiride treatment, while neither the dopamine receptor agonists nor SCH-
23390 had this effect (Fig. 4B). Furthermore, sulpiride also increased the fraction of BrdU+ cells expressing TH 
(Fig. 4C). Although we found that the GABAA receptor blocker, picrotoxin, increased proliferation, the fraction 
of TH+ cells did not increase in the cultures (Fig. 4B), indicating a selective role for dopamine receptor signalling 
in dopamine neurogenesis. To further validate these observations and to analyse if dopamine signalling could 
regulate the number of dopamine neurons generated from mouse embryonic stem cells (mESCs) we induced 
neurogenesis in mESC-derived midbrain cultures and found that dopamine decreased the fraction of EdU+/TH+ 
cells whereas both haloperidol and sulpiride increased it (Fig. 4D,E). These in vitro data are consistent with the 
results obtained in vivo and indicate that dopamine receptor antagonists may serve as a tool to enhance dopamine 
neurogenesis.
Discussion
In this work we characterized ventral midbrain ventricular cells in the Lmx1a lineage through embryogenesis into 
adulthood in mice. These cells retain expression of nestin, Sox2, Sox3 and prominin beyond the period of normal 
dopamine neurogenesis during embryonic development and even in the adult, suggesting that they might have 
sustained progenitor cell properties. We further showed that proliferation and subsequent neurogenic conversion 
of these cells was enhanced by dopamine receptor antagonist treatment, an effect that extended beyond the bulk 
of normal embryonic dopamine neurogenesis.
Several previous studies have shown that neurotransmitters influence neurogenesis both during embryonic 
development and in the adult brain and spinal cord in several species, e.g. in mammals, salamanders and zebraf-
ish21–24. The role of dopamine signalling in neurogenesis in the mammalian brain was addressed in different 
experimental settings, which collectively indicated region- and cell-type specific effects. Dopamine depletion 
has been seen to decrease cell proliferation in the dentate gyrus and subventricular zone in some of these stud-
ies25–30, while others documented increased cell proliferation13,31,32. Furthermore, observations in gerbils and in 
rats showed increased cell proliferation in dentate gyrus33, thus revealing that haloperidol treatment can increase 
the number of stem cells and the proliferation of transient-amplifying progenitors in the SVZ34.
Importantly, the present work is the first to address how modulating dopamine signalling influences cell pro-
liferation and neurogenesis in the developing mammalian midbrain after the peak of dopamine neurogenesis. 
Although the effects in mice, as shown here, were rather modest, the results are in line with previous findings 
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in aquatic salamanders, which demonstrated increased midbrain dopamine neurogenesis upon haloperidol 
treatment17. This indicates an evolutionary conserved regulatory mechanism by which dopamine suppresses 
the proliferation of dopamine progenitors and ultimately neurogenesis. Whether dopamine acts in a negative 
feedback-like manner in the mammalian midbrain remains to be proven. However, it is noteworthy that several 
reports identify regionally committed stem and progenitor cells that respond to varying levels of neurotransmit-
ters. For example, the neurotransmitter (GABA) negatively controls proliferation of cells in the subventricular 
zone and in the rostral migratory stream35–37, and quiescent neural stem cells respond tonically to GABA by 
means of γ 2-subunit-containing GABAA receptors in the adult dentate gyrus38. Hence, a plausible hypothesis is 
that a function of dopaminergic innervation of Lmx1a-expressing cells could be to maintain progenitors in quies-
cence, a state that can be transitioned into proliferation upon dopamine receptor antagonist treatment.
Dopamine neurogenesis in the adult salamander midbrain is critically dependent on reduced dopamine levels. 
Our observations raise the possibility that neurogenesis could be activated from resident Lmx1a-expressing cells 
by modulation of dopamine receptor signalling also in the postnatal mammalian brain. However, several signif-
icant ontogenetic changes occur as the region harbouring these cells transition beyond embryonic neurogenesis. 
The number of Lmx1a-expressing cells decreases, the expression level of Lmx1a in these cells is decreased and 
their processes become smaller and do not extend far beyond the aqueduct in the adult brain. As these processes 
likely support cell migration during development their disappearance may contribute to the diminution of neu-
rogenesis in the adult midbrain. Nevertheless our findings warrant further experiments targeting the neurogenic 
potential of Lmx1a-expressing population in the adult midbrain.
Figure 4. Dopamine receptor antagonists increased cell proliferation and neurogenesis in embryonic 
midbrain and mESC cultures. The fraction of primary midbrain cells increased significantly upon treatment 
with the dopamine receptor (DR) antagonists haloperidol and sulpiride, but not with SCH-23390. Dopamine 
and the DR agonist quinpirole did not increase cell proliferation. The GABAA receptor agonist muscimol 
decreased proliferation, while the GABAA receptor blocker, picrotoxin, increased proliferation (A). Only the DR 
antagonists haloperidol and sulpiride increased the fraction of TH+ cells in primary midbrain cultures (B). The 
DR antagonist sulpiride increased the fraction of BrdU+ TH+ cells in primary midbrain cultures (C). Dopamine 
(DA) decreased, while haloperidol (Hal) and sulpiride (Sulpi) increased the fraction of EdU+ TH+/TH+ cells 
derived from mESCs (D,E). (A,B,D, *P < 0.05; **P < 0.01; ***P < 0.001, 1-way ANOVA and Newman-Keuls 
post hoc test, (C), unpaired Student’s t test). Scale bars: 20 μ M.
www.nature.com/scientificreports/
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Methods
Ethics statement. All the work involving animals or human subjects/tissues was carried out in accordance 
with the Code of Ethics of the World Medical Association (Declaration of Helsinki) and with national legisla-
tion and institutional guidelines. Animal procedures were approved by the regional animal ethics review board 
(Stockholms Norra Djurförsöksetiska nämnd) and the Florey Institute of Neuroscience and Mental Health 
animal ethics committee. Ethical approval for the use of human post mortem samples was obtained from the 
regional ethical review board in Stockholm, Sweden (Regionala Etikprövningsnämnden, Stockholm, EPN), eth-
ical approval number 2012/111-31/1. All post mortem human tissues were obtained from the National Disease 
Research Interchange (NDRI, www.ndriresource.org) with the written informed consent from the donors or the 
next of kin.
Animals. All mouse lines were maintained on a C57Bl/6 background. The following transgenic mouse lines 
were utilized: Lmx1aeGFP/+ mice8; floxNurr1DATCre (Nurr1CKO) mice, generated by crossing floxed Nurr1 
mice20 with mice carrying Cre inserted into the DAT gene locus39; and DATYFPxROSA26 mice, which were gen-
erated by crossing B6.129X1-Gt(ROSA)26Sortm1(EYFP)cos/J mice (Jackson laboratory #006148) with DAT-CreERT2 
mice; D2R knock-out (D2R KO) mice and wild-type littermates40 (Jackson laboratory #003190).
BrdU delivery through subcutaneous pumps. The subcutaneous pump (Alzet, Model 2001) was filled 
with BrdU solution (0,08 mg/mL, Sigma), diluted in 60% DMSO and 40% dH2O.
Haloperidol in vivo administration. Haloperidol (Sigma) solution was prepared in acetic acid and saline 
and neutralized by addition of NaOH. For the proliferation experiments, pregnant dams received two daily injec-
tions of haloperidol (3 mg/kg) or vehicle at E12.5, E13.5, E14.5, E15.5 or E16.5, and were sacrificed the day after. 
For chase experiment performed from E15.5 to E18.5, animals were daily injected with vehicle or haloperidol 
(1.5 mg/kg).
Mouse tissue processing. Adult mice were anesthetized with avertin (tribromoethanol, Sigma) at 0.5–
0.6 mg/g body weight i.p. and perfused intracardially with phosphate buffered saline (PBS) (Invitrogen) and sub-
sequently 4% paraformaldehyde (Sigma). Brains were dissected, postfixed for 2–6 h in 4% PFA, cryoprotected in 
20% and then 30% sucrose, sectioned (30–40 μ m), serially collected and stored in antifreeze solution (30% glyc-
erol, 30% ethoxyethanol, 40% PBS) at − 20 °C until used. Pregnant dams were anesthetised by CO2 and sacrificed 
by cervical dislocation and embryos collected. For immunohistochemistry and in situ hybridization, collected 
embryos were postfixed in 4% PFA (1–3 h depending on the age of the embryo), cryoprotected in 20% and sub-
sequently in 30% sucrose, embedded in OCT (TissueTek), sectioned at 12–20 μ m, serially collected and stored 
at − 80 °C.
Human tissue processing. The tissues were fixed in 4% PFA, sequentially placed through sucrose gradients 
(2%, 10%, 20% and 30%) for cryoprotection and sectioned on a freezing microtome (Microme HM430) at 40 μ m 
thickness and serially collected. Tissues were subjected to antigen retrieval (0.01 M citric acid buffer, pH 6.0 for 
20 min at 95 °C) and blocking of endogenous peroxidases (3% H2O2 in 50% methanol in PBS) prior to staining41.
Histological procedures for mouse and human tissues. For immunofluorescent staining of mouse 
tissues, sections were rinsed with PBS and incubated with blocking buffer (PBS, 5–10% normal donkey serum; 
NDS or normal goat serum; NGS (Jackson Laboratories), 0.1% Triton-X100) for 1 h prior to incubation with 
primary antibodies (Supplementary Table 1) in blocking buffer overnight at 4 °C. The tissue sections were subse-
quently incubated in Alexafluor secondary antibodies (1:500) for 1 h, and rinsed in PBS. Hoechst 33342 (4 μ g/ml) 
was used for counterstaining and tissue sections were mounted onto slides in Mowiol 4–88 (Calbiochem). 
Confocal analysis was performed using a Zeiss LSM510/Meta Station (Thornwood, NY, http://www.zeiss.com). 
For identification of signal co-localization within a cell, optical thickness was kept to a minimum, and orthog-
onal reconstructions were obtained. Each experiment was performed in triplicate and all counts were done in a 
double-blind fashion.
Sections from human postmortem tissues were incubated with blocking buffer for 1 h. Subsequently, sections 
were incubated overnight at 4 °C using goat anti-tyrosine hydroxylase antibody (1:300, PelFreez). Sections were 
washed in PBS and incubated with a biotinylated secondary antibody (1:200; Vector Laboratories) for 1 h at room 
temperature, followed by incubation in streptavidin-biotin complex (Vectastain ABC kit Elite, Vector laborato-
ries) for 1 h and visualized by incubation in 3,3′ -diaminobenzidine solution (DAB, Vector Laboratories). Nuclei 
were counterstained using Myers hematoxylin (Histolab) for 1–2 min, rinsed in ddH20, quickly immersed in 70% 
ethanol containing 36 mM HCl to remove background staining, followed by another rinse in ddH20. Sections 
were subsequently dehydrated by sequential steps in increasing ethanol concentration accordingly; 25% etha-
nol (2 min), 70% ethanol (2 min), differentiator (75% ethanol containing 96 mM acetic acid) (1 min), 95% etha-
nol (2 min), 100% ethanol (2 min), xylene (2 × 2 min) and coverslipped using Mountex (Histolab)41. Brightfield 
images were captured using a Zeiss Axio Imager M1 Upright microscope. Control experiments were performed 
for all stainings by omitting either primary or secondary antibodies.
Quantification of cell numbers and intensity measurements in vivo. The signal intensity of tyros-
ine hydroxylase fiber innervation of the midbrain aqueduct was quantified using Image J (http://rsb.info.nih.gov/
ij/). Values are displayed as relative intensity of signal in controls. Quantification of the number of Ki67+ eGFP+ 
cells, using immunofluorescent staining coupled with confocal analysis, was performed at E12.5 (1/5 sections 
counted), E15.5 (1/6 sections counted) and E18.5 (1/7.5 sections counted) (Fig. 1Q–T). The total number of 
Ki67+ cells in the ventral midbrain regions were retrieved by using the counts and taken into account the total 
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number of sections, the average diameter of the cells (10 μ m), by performing the Abercrombie correction, accord-
ing to P = A • (M/L + M) • n, where P is the average number of nuclear points, A the number of nuclei identified/
section, M is the thickness of the section, L the average length of the cell (in μ m) and n the number of sections. TH 
innervation of the midbrain aqueduct in Nurr1CKO and wild-type littermate mice was conducted on confocal 
projection images derived from z-stacks of identical depth using the Image J software (https://imagej.nih.gov/ij/).
For quantification of Ki67+ cells in the D2R KO mice analysis was conducted at E11.5 (1/5 sections counted) 
(Fig. 3E). To evaluate the number ventral eGFP+ pH3+ cells or eGFP+ BrdU+ cells, a Zeiss upright microscope 
was used. The number of cells was quantified under 63X magnification with the optical fractionator method on 
a systematic random sampling of every fifth sections along the rostro-caudal axis. To evaluate the number of 
BrdU+ cells in the prospective VTA and SN, 20x images encompassing the entire midbrain were generated and 
cell numbers within the TH+ area counted (number of BrdU+ cells/TH+ area measured in μ m3) in 3 or 4 sections. 
To analyse the percentage of BrdU+TH+/BrdU+ cells, 40x confocal images along the entire Z-axis (12 μ m) using 
1 μ m intervals were counted. The co-labeled cells were analyzed with Imarys software.
In situ hybridization. In situ hybridization on sections was carried out essentially as previously described42 
using a probe for Lmx1a6.
Mouse primary midbrain cultures and immunocytochemistry. Brains from E11.5 mice were obtained 
and the midbrain region was dissected, mechanically dissociated, plated on poly-d-lysine (150,000 cells/cm2), 
and grown in serum-free N2 media consisting of F12/DMEM (1:1) with insulin (10 ng/ml), apo-transferrin (100 μ g/ml), 
putrescine (100 μ M), progesterone (20 nM), selenium (30 nM), glucose (6 mg/ml), BSA (1 mg/ml) and FGF2 
(10 ng/ml). Cells were treated for 3 days in vitro with either dopamine (10 μ M, Sigma), haloperidol (1 μ M, Sigma), 
quinpirole (10μ M, Tocris Bioscience), dihydrexidine (10 μ M, Tocris Bioscience), muscimol (30 μ M, Sigma) 
sulpiride (10 μ M, Tocris Bioscience), SCH-23390 (10 μ M, Santa Cruz Biotechnology), picrotoxin (30 μ M, Tocris 
Bioscience) or media only and then processed for immunocytochemistry. For BrdU analysis, cells were treated 
with BrdU 1 hour after plating. After a further 2 days in culture, cells were treated for 30 minutes with 2N HCl, 
and processed for immunocytochemistry.
Differentiation of mouse embryonic stem cells (mESCs). R1 mESCs (Nagy’s lab, MSH, Toronto, 
Canada) were cultured and differentiated on PA6 stromal feeders (RCB1127, Riken BRC Cell Bank, Japan)43. 
Specifically, mESCs were plated at low density (100 cells/cm2) on a confluent layer of PA6 cells and were grown in 
Serum Replacement Medium with Noggin (300 ng/ml; R&D Systems) as previously described44. At day 5, 200 ng/ml 
Shh (R&D Systems) and 25 ng/mL Fgf8b (R&D Systems) were added to the medium. At day 8, the medium was 
switched to N2 medium containing Shh, Fgf8b, and Fgf2 (10 ng/ml, R&D Systems). At day 10 of differentia-
tion the cells were pulsed with EdU (10 μ M, Life Technologies). From day 11 of differentiation, Shh, Fgf8b and 
Fgf2 were removed from the N2 medium and replaced by BDNF (20 ng/ml, R&D Systems), GDNF (20 ng/ml, 
R&D Systems), and ascorbic acid (0.2 mM). Between day 8–15, cells were treated daily with either dopamine (10 μ M), 
haloperidol (1 μ M), quinpirole (10 μ M), sulpiride (10 μ M) or media only. At day 15, cells were fixed in 4% PFA 
and processed for immunocytochemistry as described below.
Immunohistochemistry of mESC and primary cultures and in vitro quantifications. Cells were 
incubated for 1 h in blocking buffer prior to overnight incubation with the primary antibodies (Supplementary 
Table 1) at 4 °C. The coverslips were subsequently incubated in secondary antibodies (1:500, Life Technologies 
or Jackson Immunoresearch) for 1 h, and rinsed in PBS. EdU determinations were done according to Clik-it 
EdU kit (Life Technologies). DAPI or Hoechst (Sigma-Aldrich) was used for counterstaining. Each condition 
was analyzed in duplicates for three independent experiments (n = 3). Specifically, for the primary cultures, cells 
positive for each marker were counted in 8 consecutive fields/well. For the mESC-derived cultures, the number of 
TH+ and TH+ EdU+ cell in each well were quantified in 15 fields with an Olympus FV1000 confocal microscope.
Statistical analysis. Prism (GraphPad software inc) and Statistica 8.0 (Statsoft) software were used for the 
statistical analyses. Experimental data was analysed using either student’s t test, 1-way ANOVA or 2-way ANOVA. 
All data are presented as mean ± SEM.
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